How COVID-19 Provided Opportunities For Startups To Prove Their Mettle
Source: Life Science Leader
In this executive virtual roundtable (EVR) component, Steffen Mueller, Ph.D., cofounder and CSO, Codagenix, a clinical-stage synthetic-biology company that uses software to recode the genomes of viruses, constructing live-attenuated vaccines or viruses to prevent viral infections or treat solid tumors, explains his company’s ramp up to develop and test a corona virus vaccine (COVI-VAC). Adding to the conversation on lessons learned via the pandemic is Rahul Aras, Ph.D., CEO of Iterion Therapeutics, a clinical stage company developing cancer therapeutics.
This website uses cookies to ensure you get the best experience on our website. Learn more